Cocaine and metabolite concentrations in plasma during repeated oral administration: Development of a human laboratory model of chronic cocaine use

Journal of Analytical Toxicology

Volumn 22, Issue 6, 1998, Pages 435-444

  Jufer, Rebecca A ^a   Walsh, Sharon L ^b   Cone, Edward J ^a  

^a NIDA Addiction Research Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYLECGONINE; BENZOYLNORECGONINE; COCAINE; DRUG METABOLITE; ECGONINE METHYL ESTER; NORCOCAINE;

ABSORPTION; AREA UNDER THE CURVE; ARTICLE; DRUG ABUSE; DRUG DEPENDENCE; DRUG WITHDRAWAL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; METABOLISM; PLASMA; SOLID PHASE EXTRACTION;

EID: 0031697181     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/22.6.435     Document Type: Article

References (25)

1. Substance Abuse and Mental Health Services Administration. Preliminary results from the 1996 National Household Survey on Drug Abuse. SAMHSA, 1997.
2. National Institute on Drug Abuse. Cocaine abuse. NIDA Capsules 1-4 (1997).
3. J.J. Ambre, S.M. Belknap, J. Nelson, T.I. Ruo, S.O. Shin, and A.J. Atkinson. Acute tolerance to cocaine in humans. Clin. Pharmacol. Ther. 44:1-8 (1988).
4. K.M. Kumor, M.A. Sherer, J. Gomez, E. Cone, and J.H. Jaffe. Subjective response during continuous infusion of cocaine. Pharmacol. Biochem. Behav. 33: 443-452 (1989).
5. M.C. Rowbotham, R.T. Jones, N.L. Benowitz, and P. Jacob, III. Trazodone - oral cocaine interactions. Arch. Gen. Psychiatry 41: 895-899 (1984).
6. C. Van Dyke, P. Jatlow, J. Ungerer, P.C. Barash, and R. Byck. Oral cocaine: plasma concentrations and central effects. Science 200: 211-213 (1978).
7. P. Wilkinson, C. Van Dyke, P. Jatlow, P. Barash, and R. Byck. Intranasal and oral cocaine kinetics. Clin. Pharmacol. Ther. 27: 386-394 (1980).
8. E.J. Cone. Pharmacokinetics and pharmacodynamics of cocaine, J. Anal. Toxicol. 19: 459-478 (1995).
9. R.C. Baselt. Stability of cocaine in biological fluids. J. Chromatogr. 268: 502-505 (1983).
10. V.D. Gupta. Stability of cocaine hydrochloride solutions at various pH values as determined by high-pressure liquid chromatography. Int. J. Pharmacol. 10: 249-257 (1982).
11. M.R. Brzezinski, T.L. Abraham, C.L. Stone, R.A. Dean, and W.F. Bosron. Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine. Biochem. Pharmacol. 48(9): 1747-1755 (1994).
12. R.A. Dean, C.D. Christian, R.H.B. Sample, and W.F. Bosron. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J. 5: 2735-2739 (1991).
13. E.V. Pindel, N.Y. Kedishvili, T.L. Abraham, M.R. Brzezinski, J. Zhang, R.A. Dean, and W.F. Bosron. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J. Biol. Chem. 272 (23): 14769-14775 (1997).
14. T. Inaba, D.J. Stewart, and W. Kalow. Metabolism of cocaine in man. Clin. Pharmacol. Ther. 23: 547-552 (1978).
15. T.J. Lynch, C.E. Mattes, A. Singh, R.M. Bradley, R.O. Brady, and K.L. Dretchen. Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol. App. Pharmacol. 145: 363-371 (1997).
16. F.M. Ndikum-Moffor, T.R. Schoeb, and S.M. Roberts. Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine. J. Pharmacol. Exp. Ther. 284: 413-419 (1998)
17. B.W. LeDuc, P.R. Sinclair, L. Shuster, J.F. Sinclair, J.E. Evans, and D.J. Greenblatt. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 46: 294-300 (1993).
18. F.P. Guengerich and T. Shimada. Human cytochrome P450 enzymes and chemical carcinogenesis. In Human Drug Metabolism. From Molecular Biology to Man. E.H. Jeffery, Ed. CRC Press, Boca Raton, FL, 1993, pp 5-12.
19. K. Watanabe, Y. Hida, T. Matsunaga, I. Yamamoto, and H. Yoshimura. Formation of p-hydroxycocaine from cocaine by hepatic microsomes of animals and its pharmacological effects in mice. Biol. Pharm. Bull. 16(10): 1041-1043 (1993).
20. M. Rowland and T.N. Tozer. Clinical Pharmacokinetics: Concepts and Applications. 2nd ed. Lea and Febiger, Philadelphia, PA, 1989.
21. J.A. Sandberg, L.J. Murphey, and G.D. Olsen. In vitro hepatic biotransformation of cocaine in maternal and fetal guinea pigs. Induction of cocaine N-demethylation with cocaine pretreatment. Drug Metab. Dispos. 21: 390-395 (1993).
22. E.J. Cone, M. Hillsgrove, and W.D. Darwin. Simultaneous measurement of cocaine, cocaethylene, their metabolites, and "Crack" pyrolysis products by gas chromatography-mass spectrometry. Clin. Chem. 40: 1299-1305 (1994).
23. J. Liddell, G.E. Newman, and D.F. Brown. A pseudocholinesterase variant in human tissues. Nature 198: 1090-1091 (1963).
24. P.D. Kroboth, J.W. McAuley, F.J. Kroboth, R.J. Bertz, and R.B. Smith. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J. Clin. Psychopharm. 15: 259-262 (1995).
25. C.E. Mattes, T.J. Lynch, A. Singh, R.M. Bradley, P.A. Kellaris, R.O. Brady, and K.L Dretchen. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol. App. Pharmacol. 145: 372-380 (1997).